<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns:ifp="http://www.ifactory.com/press" xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9">
  <ifp:contentType>ARTICLE</ifp:contentType>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-pxxx.xml</sm:loc>
    <ifp:title>NCCN News</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-pxlvi.xml</sm:loc>
    <ifp:title>Oncology Research Program</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p753.xml</sm:loc>
    <ifp:title>Getting Practical About Recertification</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p754.xml</sm:loc>
    <ifp:title>Keeping Up in the Community</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p757.xml</sm:loc>
    <ifp:title>Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p761.xml</sm:loc>
    <ifp:title>NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p772.xml</sm:loc>
    <ifp:title>Developments in Molecular Testing and Biosimilars</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p790.xml</sm:loc>
    <ifp:title>Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p797.xml</sm:loc>
    <ifp:title>Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p804.xml</sm:loc>
    <ifp:title>Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p835.xml</sm:loc>
    <ifp:title>Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p841.xml</sm:loc>
    <ifp:title>Integrating Immunotherapy Into the Management of Renal Cell Carcinoma</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p783.xml</sm:loc>
    <ifp:title>Overuse of Chest CT in Patients With Stage I and II Breast Cancer: An Opportunity to Increase Guidelines Compliance at an NCCN Member Institution</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
  <sm:url>
    <sm:loc>https://harbor-dev.pubfactory.com/view/journals/jnccn/15/6/article-p849.xml</sm:loc>
    <ifp:title>Evidence-Based Guidelines: Optimizing Imaging in Cancer Care</ifp:title>
    <sm:lastmod>2019-01-04</sm:lastmod>
  </sm:url>
</urlset>
